Samantha Hoffman
Family · North Babylon, NYNPI 1144869397
Payments from drug & device makers
Across 84 payments — averaging $29.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$592
- Abbott$339
- Medtronic$291
- Amgen$135
- Renalytix AI, Inc.$118
- Novo Nordisk$115
- plus $881 from 18 others
What the payments were for
- Food & beverage$2,470100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $592 |
| Abbott | 2 | $339 |
| Medtronic | 2 | $291 |
| Amgen | 7 | $135 |
| Renalytix AI, Inc. | 1 | $118 |
| Novo Nordisk | 5 | $115 |
| Edwards Lifesciences | 3 | $106 |
| Lilly USA, LLC | 4 | $104 |
| Pfizer | 4 | $98 |
| Baxter Healthcare | 1 | $78 |
| Johnson & Johnson | 4 | $74 |
| Heartflow, Inc. | 3 | $69 |
| Merck | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 2 | $44 |
| Smith+Nephew | 2 | $43 |
| Abiomed | 1 | $36 |
| Exact Sciences | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| Electromed, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,470 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $59,410 |
| EntrestoSacubitril/Valsartan | 38 | $46,223 |
| JardianceEmpagliflozin | 11 | $16,941 |
| Repatha SyringeEvolocumab | 11 | $5,059 |
| Nebivolol Hcl | 21 | $2,263 |
| Potassium Chloride | 16 | $940 |
| Metoprolol Succinate | 75 | $911 |
| Atorvastatin Calcium | 75 | $686 |
| Prasugrel Hcl | 12 | $486 |
| Rosuvastatin Calcium | 68 | $484 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 16 | $357 |
| ClopidogrelClopidogrel Bisulfate | 34 | $317 |
| Losartan Potassium | 41 | $272 |
| Lisinopril | 62 | $250 |
| Pravastatin Sodium | 14 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $98 | $59,41051 claims |
| NovartisEntresto | $592 | $46,22338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.
Other family in North Babylon
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.